Aromatase Inhibitor–Related Symptoms Reported by Postmenopausal Women with Nonmetastatic, Estrogen Receptor–Positive Breast Cancer: A Systematic Review
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 1,04 MB, PDF-dokument
Purpose
The objective of this systematic review was to establish an overview of aromatase inhibitor–related symptoms reported by postmenopausal women with nonmetastatic, estrogen receptor–positive breast cancer.
Data Sources
Eight databases (PubMed, Cochrane, Cumulative Index to Nursing and Allied Health Literature [CINAHL], Ovid EMBASE, Ovid MEDLINE, PsycINFO, Scopus, and Web of Science) were searched for trials published between January 2004 and November 2021. Inclusion criteria were studies exploring patient-reported aromatase inhibitor–related symptoms in postmenopausal women with nonmetastatic estrogen receptor–positive breast cancer. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Mixed Method Appraisal Tool were used to rate the quality of the trials included. Of 325 full-text papers, 10 were included. Patient-reported symptoms were clustered by using the European Organization for Research and Treatment of Cancer Quality of Life C30 questionnaire domains. Additional domains were used to cluster other symptoms mentioned: menopausal, sex-related, body alteration, and eye-related. The following clusters were the most frequently presented: sex-related (14 symptoms), pain (9 symptoms), insomnia (5 symptoms), and menopausal (5 symptoms).
Conclusion
The target group reported a variety of symptoms related to aromatase inhibitors. No tools are currently available to measure all the symptoms reported, indicating a need to revise the tools to acknowledge additional symptoms. Prospective studies are needed to investigate the prevalence of aromatase inhibitor–related symptoms in women with breast cancer.
The objective of this systematic review was to establish an overview of aromatase inhibitor–related symptoms reported by postmenopausal women with nonmetastatic, estrogen receptor–positive breast cancer.
Data Sources
Eight databases (PubMed, Cochrane, Cumulative Index to Nursing and Allied Health Literature [CINAHL], Ovid EMBASE, Ovid MEDLINE, PsycINFO, Scopus, and Web of Science) were searched for trials published between January 2004 and November 2021. Inclusion criteria were studies exploring patient-reported aromatase inhibitor–related symptoms in postmenopausal women with nonmetastatic estrogen receptor–positive breast cancer. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Mixed Method Appraisal Tool were used to rate the quality of the trials included. Of 325 full-text papers, 10 were included. Patient-reported symptoms were clustered by using the European Organization for Research and Treatment of Cancer Quality of Life C30 questionnaire domains. Additional domains were used to cluster other symptoms mentioned: menopausal, sex-related, body alteration, and eye-related. The following clusters were the most frequently presented: sex-related (14 symptoms), pain (9 symptoms), insomnia (5 symptoms), and menopausal (5 symptoms).
Conclusion
The target group reported a variety of symptoms related to aromatase inhibitors. No tools are currently available to measure all the symptoms reported, indicating a need to revise the tools to acknowledge additional symptoms. Prospective studies are needed to investigate the prevalence of aromatase inhibitor–related symptoms in women with breast cancer.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 151487 |
Tidsskrift | Seminars in Oncology Nursing |
Vol/bind | 39 |
Udgave nummer | 5 |
Antal sider | 12 |
ISSN | 0749-2081 |
DOI | |
Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
This research was funded by the Research Fund of Rigshospitalet, Copenhagen University Hospital, Denmark (grant No.: E-23384-04) , the Novo Nordisk Foundation, Denmark (grant No.: NNF22OC0080433 ), and Minister Erna Hamilton Foundation, Denmark (grant No.: 06-2019 ). The funders played no role in any part of the design, conduction, analysis, or publication plan for this study.
Publisher Copyright:
© 2023 The Authors
ID: 377804828